- Home
- INBX vs CRDF Comparison
INBX vs CRDF Comparison
Compare INBX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- CRDF
- Stock Information
- Founded
- INBX 2010
- CRDF 1999
- Country
- INBX United States
- CRDF United States
- Employees
- INBX N/A
- CRDF N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBX Health Care
- CRDF Health Care
- Exchange
- INBX Nasdaq
- CRDF Nasdaq
- Market Cap
- INBX 168.1M
- CRDF 196.2M
- IPO Year
- INBX 2020
- CRDF N/A
- Fundamental
- Price
- INBX $11.18
- CRDF $2.66
- Analyst Decision
- INBX Hold
- CRDF Strong Buy
- Analyst Count
- INBX 1
- CRDF 4
- Target Price
- INBX N/A
- CRDF $12.25
- AVG Volume (30 Days)
- INBX 97.5K
- CRDF 1.1M
- Earning Date
- INBX 05-20-2025
- CRDF 05-08-2025
- Dividend Yield
- INBX 7.56%
- CRDF N/A
- EPS Growth
- INBX N/A
- CRDF N/A
- EPS
- INBX 112.62
- CRDF N/A
- Revenue
- INBX $200,000.00
- CRDF $587,000.00
- Revenue This Year
- INBX N/A
- CRDF N/A
- Revenue Next Year
- INBX N/A
- CRDF N/A
- P/E Ratio
- INBX $0.10
- CRDF N/A
- Revenue Growth
- INBX N/A
- CRDF N/A
- 52 Week Low
- INBX $10.80
- CRDF $2.01
- 52 Week High
- INBX $18.95
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- INBX 38.27
- CRDF 42.40
- Support Level
- INBX $10.90
- CRDF $2.42
- Resistance Level
- INBX $12.60
- CRDF $2.87
- Average True Range (ATR)
- INBX 0.86
- CRDF 0.19
- MACD
- INBX -0.03
- CRDF 0.01
- Stochastic Oscillator
- INBX 14.28
- CRDF 27.91
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.